NeurolMed
NeurolMed is a South Korean biopharmaceutical company specializing in the development of drugs derived from biomolecules and natural products targeting acute and chronic degenerative cerebral disorders such as stroke, Parkinson's, and Alzheimer's diseases. The company aims to fundamentally and definitively cure at least one disease by leveraging integrated expertise in biology and chemistry to conduct all stages of early drug development. NeurolMed's R&D strategy focuses on neuroscience, small molecule compounds, biologics, and novel strategies to overcome blood-brain barrier challenges, with a pipeline emphasizing oncology and central nervous system disorders. The company also plans to develop its own AI platform combining advanced computer science and semiconductor-based AI technology. NeurolMed has achieved multiple patents and certifications, participated in notable startup programs, and secured seed investments, positioning itself as a promising player in transformative medicine for serious brain-related diseases.
NeurolMed
NeurolMed is a South Korean biopharmaceutical company specializing in the development of drugs derived from biomolecules and natural products targeting acute and chronic degenerative cerebral disorders such as stroke, Parkinson's, and Alzheimer's diseases. The company aims to fundamentally and definitively cure at least one disease by leveraging integrated expertise in biology and chemistry to conduct all stages of early drug development. NeurolMed's R&D strategy focuses on neuroscience, small molecule compounds, biologics, and novel strategies to overcome blood-brain barrier challenges, with a pipeline emphasizing oncology and central nervous system disorders. The company also plans to develop its own AI platform combining advanced computer science and semiconductor-based AI technology. NeurolMed has achieved multiple patents and certifications, participated in notable startup programs, and secured seed investments, positioning itself as a promising player in transformative medicine for serious brain-related diseases.